ING Groep NV Sells 255,934 Shares of Pfizer Inc. (NYSE:PFE)

ING Groep NV lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 25.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 757,296 shares of the biopharmaceutical company's stock after selling 255,934 shares during the period. ING Groep NV's holdings in Pfizer were worth $19,190,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Commonwealth Equity Services LLC grew its holdings in Pfizer by 2.6% during the first quarter. Commonwealth Equity Services LLC now owns 4,602,476 shares of the biopharmaceutical company's stock valued at $116,627,000 after purchasing an additional 117,370 shares during the period. Raiffeisen Bank International AG grew its holdings in Pfizer by 38.4% during the first quarter. Raiffeisen Bank International AG now owns 53,831 shares of the biopharmaceutical company's stock valued at $1,357,000 after purchasing an additional 14,937 shares during the period. Blair William & Co. IL grew its holdings in Pfizer by 0.9% during the first quarter. Blair William & Co. IL now owns 2,290,198 shares of the biopharmaceutical company's stock valued at $58,034,000 after purchasing an additional 20,179 shares during the period. Argent Trust Co grew its holdings in Pfizer by 3.1% during the first quarter. Argent Trust Co now owns 239,359 shares of the biopharmaceutical company's stock valued at $6,065,000 after purchasing an additional 7,235 shares during the period. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its holdings in Pfizer by 3.6% during the first quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 46,500 shares of the biopharmaceutical company's stock valued at $1,178,000 after purchasing an additional 1,600 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.3%

Shares of PFE stock opened at $23.56 on Tuesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The stock's 50 day simple moving average is $24.37 and its two-hundred day simple moving average is $24.53. The company has a market cap of $133.95 billion, a PE ratio of 17.07, a price-to-earnings-growth ratio of 0.85 and a beta of 0.52.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.3%. Pfizer's dividend payout ratio is 124.64%.

Analysts Set New Price Targets

Several analysts have issued reports on PFE shares. Redburn Atlantic cut their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Bank of America boosted their price objective on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. TD Cowen lowered their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. Finally, UBS Group boosted their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.